Core Viewpoint - The company is utilizing idle funds from its non-public stock issuance for cash management to enhance the value of raised funds and increase company earnings while ensuring the normal implementation of investment projects and the safety of raised funds [1][3]. Cash Management Purpose - The cash management aims to better preserve and increase the value of the raised funds, thereby benefiting all shareholders [1]. Cash Management Amount - The company plans to use 100 million yuan (10,000 million) of idle funds from its non-public stock issuance for cash management [1][3]. Fund Source - The funds are sourced from the net proceeds of a non-public stock issuance approved by the China Securities Regulatory Commission, totaling approximately 3.05 billion yuan [1][2]. Investment Project Progress - As of December 31, 2024, the investment projects funded by the non-public stock issuance are as follows: - Expansion of in vitro diagnostic product capacity: Adjusted total investment of 1.43 billion yuan, with cumulative investment of 523.92 million yuan - In vitro diagnostic product R&D center: Adjusted total investment of 833 million yuan, with cumulative investment of 349.66 million yuan - Diagnostic instrument industrial park: Adjusted total investment of 201.89 million yuan, with cumulative investment of 162.18 million yuan [2]. Cash Management Types and Procedures - The cash management products include structured deposits, large certificates of deposit, treasury reverse repos, broker income certificates, and broker wealth management products, all of which are low-risk and have high liquidity [3][5]. Cash Management Duration - The duration of the cash management products will not exceed 12 months [5]. Financial Data Overview - As of March 31, 2025, the company reported total assets of approximately 1.20 billion yuan and total liabilities of approximately 299.82 million yuan, with net assets attributable to shareholders of approximately 887.69 million yuan [7]. Impact of Cash Management - The cash management is expected to improve the efficiency of fund utilization and generate certain investment returns for shareholders, without affecting the normal operation of investment projects [7].

证券代码：603658 证券简称：安图生物 公告编号：2025-052 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、非公开发行股票闲置募集资金进行现金管理情况 1 现金管理种类：券商收益凭证； 现金管理金额：10,000 万元非公开发行股票闲置募集资金； 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会 议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，公司 拟分别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超 过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收益 凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额度范 围内，资金可在 12 ...

证券代码：603658 证券简称：安图生物 公告编号：2025-051 郑州安图生物工程股份有限公司 关于开立募集资金现金管理产品专用结算账户的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"）于2024年12月11日召 开第五届董事会第二次会议、第五届监事会第二次会议，审议通过《关于使用闲 置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金投资项目建 设和募集资金使用的情况下，公司拟分别使用不超过1.7亿元公开发行可转换公 司债券闲置募集资金和不超过17亿元非公开发行股票闲置募集资金进行现金管 理，分别用于购买单次持有期限不超过12个月的结构性存款、大额存单、国债逆 回购、券商收益凭证、券商理财产品等安全性高、流动性好的保本型产品。在上 述额度范围内，资金可在12个月内滚动使用。具体内容详见公司于2024年12月12 日在上海证券交易所网站（www.sse.com.cn）披露的《安图生物关于使用闲置募 集资金进行现金管理的公告》（公告编号：2024-093）。 ...

Core Viewpoint - Compliance is essential for the sustainable development of enterprises, and AnTu Bio has integrated compliance into every aspect of its operations, from R&D to financial management [1][2]. Group 1: Compliance Management - AnTu Bio emphasizes compliance training for new employees, incorporating real business scenarios to instill a compliance mindset [2]. - The management team includes compliance decision-making in daily operations, holding monthly simulations to embed compliance responsibilities across all processes [2]. - Supplier compliance management is viewed as a key driver for high-quality development in the industry, with strict standards for supplier qualification and tax credit reviews [2]. Group 2: Tax Policies and R&D Investment - Recent tax reduction policies have provided financial support for enterprises to increase R&D investments, with AnTu Bio investing over 10% of its annual revenue in R&D for the past three years [3]. - AnTu Bio is set to launch 144 new products, including magnetic microparticle chemiluminescence and molecular diagnostics, in 2024 due to its sustained high R&D investment [3]. Group 3: Tax and Compliance Collaboration - The tax authority in Zhengzhou has included AnTu Bio in its "Chief Tax Officer" service list, providing tailored support and monitoring the company's operational status [4]. - A proactive approach to tax management has led to a significant cash flow relief for AnTu Bio, with a recent identification of 2.73 million yuan in incremental tax credits [4]. - AnTu Bio's strong tax credit rating has resulted in a 125.10% increase in bank credit limits since 2020 and a reduction in financing costs by 0.86 percentage points, saving over 8.65 million yuan in financial expenses in 2024 [4].

关于获得医疗器械注册证的公告 证券代码：603658 证券简称：安图生物 公告编号：2025-050 郑州安图生物工程股份有限公司 二、同类产品相关情况 上述产品上市后实际销售情况取决于未来市场的推广效果，目前尚无法预测 上述产品对公司未来营业收入的影响，敬请投资者注意投资风险。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特此公告。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）于近 日收到河南省药品监督管理局颁发的医疗器械注册证，具体如下： | 编号 | 产品名称 | 注册证编号 | 注册证 有效期 | 预期用途 | | --- | --- | --- | --- | --- | | 1 | 万古霉素检测试剂盒（液 相色谱-串联质谱法） | 豫械注准 20252400430 | 5 年 | 本产品用于体外定量检测人血清 样本中万古霉素的含量。 | | 2 | 他克莫司检测试剂盒（液 相色谱-串联质谱法） | 豫械注准 20252400436 | 年 5 | 本产品用于体外定量检测人全血 样本中他克莫司的 ...

证券代码：603658 证券简称：安图生物 公告编号：2025-049 郑州安图生物工程股份有限公司 关于使用闲置募集资金进行现金管理 赎回及进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1 现金管理种类：国债逆回购； 现金管理金额：16,000 万元非公开发行股票闲置募集资金； 履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2024 年 12 月 11 日召开第五届董事会第二次会议、第五届监事会第二次会 议，审议通过《关于使用部分闲置募集资金进行现金管理的议案》，同意 公司在确保不影响募集资金投资项目建设和募集资金使用的情况下，公司 拟分别使用不超过 1.7 亿元公开发行可转换公司债券闲置募集资金和不超 过 17 亿元非公开发行股票闲置募集资金进行现金管理，分别用于购买单次 持有期限不超过 12 个月的结构性存款、大额存单、国债逆回购、券商收益 凭证、券商理财产品等安全性高、流动性好的保本型产品。在上述额度范 围内，资金可在 12 个月内滚动使用。具体内容详见公司于 202 ...

Core Viewpoint - The article highlights the market capitalization changes of major domestic life science instrument manufacturers in China for 2025, indicating a mixed performance with significant growth for some companies and declines for others due to policy impacts and market dynamics [1][2]. Market Capitalization Summary - The top five companies by market capitalization in 2025 are Mindray Medical, Sunny Optical, BGI Genomics, Antu Bio, and Haier Biomedical [2]. - A total of 10 companies experienced growth in market capitalization compared to 2024, with Zhongke Meiling leading at a growth rate of +130.44% [2]. - Four companies saw a decline in market capitalization, with Antu Bio experiencing the most significant drop at -26.70% [2]. Policy Impact Analysis - The medical anti-corruption and centralized procurement policies have negatively affected the revenue of several companies, leading to a 35% decrease in equipment bidding volume in tertiary hospitals [3]. - Mindray Medical, despite being an industry leader, faced a revenue growth drop from 25% to 9% due to procurement delays and budget constraints from DRG payment reforms [3]. - Antu Bio's revenue decreased by 18% in 2024 due to the impact of centralized procurement on the prices of chemical luminescence reagents [4]. Growth Drivers - Companies are shifting towards technology innovation as traditional high-margin models and bundled sales strategies become less viable under centralized procurement [5]. - Domestic microscope manufacturers have seen significant market capitalization growth, with Sunny Optical (+47.04%), Yongxin Optical (+27.11%), and Motic (+69.22%) benefiting from increased demand and technological advancements [7]. - Zhongke Meiling achieved a market share increase from 3% to 8% by overcoming technical barriers in ultra-low temperature freezing equipment [8]. International Expansion and Market Strategy - Companies are increasingly focusing on international markets to seek new growth opportunities, with Mindray Medical expanding its factory in New Jersey as part of its international strategy [8]. - BGI Genomics and Motic are also pursuing CE/FDA certifications to enter European and American markets, indicating a shift from domestic competition to global opportunities [8].

Group 1 - The major shareholder Z&F INTERNATIONAL TRADING LIMITED holds 76,892,416 shares, accounting for 13.46% of the total share capital of the company [1] - Z&F has reduced its holdings by 260,000 shares through block trading, representing 0.05% of the total share capital [1] - The reduction took place between March 17, 2025, and June 16, 2025, with a total amount of 10,816,000.00 yuan at a price of 41.60 yuan per share [1] Group 2 - The initial reduction plan was disclosed on February 22, 2025, with a maximum intended reduction of 3% [1] - After the reduction, Z&F's current holding is 76,632,416 shares, which is 13.41% of the total share capital [1] - The actual reduction was consistent with the previously disclosed plan, and the minimum reduction quantity was achieved [1]

证券代码：603658 证券简称：安图生物 公告编号：2025-048 郑州安图生物工程股份有限公司 关于完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"安图生物"或"公司"）于 2025 年 4 月 16 日召开第五届董事会第四次会议及第五届监事会第四次会议，审议通 过《关于变更注册资本暨修订<公司章程>的议案》，上述议案于 2025 年 5 月 8 日经公司 2024 年年度股东大会审议通过。具体内容详见公司分别于 2025 年 4 月 18 日及 2025 年 5 月 9 日在上海证券交易所网站（http://www.sse.com.cn）披露的 相关公告。 公司已于近日在河南省市场监督管理局办理完成注册资本的工商变更登记 和《公司章程》的备案手续，并取得了河南省市场监督管理局换发的新《营业执 照》，具体内容如下： 1. 统一社会信用代码：914100007167932103 2. 名称：郑州安图生物工程股份有限公司 5. 法定代表人：杨增利 6. 注册资本 ...

Core Insights - The 2024 revenue of the domestic instrument industry shows significant differentiation, with leading companies like Antu Bio achieving counter-cyclical growth while others face challenges due to market contraction and cost pressures [2][4] Group 1: Revenue and Income Disparities - The income of executives in the instrument sector has widened significantly compared to last year, primarily driven by high dividends [4] - Antu Bio's chairman, Miao Yongjun, is the only executive with an income exceeding 100 million yuan, with 99% of his income coming from dividends [4] - The dividend payout ratio for Antu Bio is 60.28% of net profit, while Tailin Bio has an even higher ratio of 91.94%, raising concerns about sustainable development [4] Group 2: Growth Drivers and Market Challenges - The biopharmaceutical supply chain and overseas markets are identified as core growth drivers, with Antu Bio's overseas revenue increasing by 36.25% year-on-year and Wanyi Technology achieving a remarkable 447% growth [4] - Traditional sectors like environmental monitoring and industrial process analysis are under severe pressure, as evidenced by the declining income of Xuedilong's chairman, which fell from 140 million yuan in 2022 to 110 million yuan in 2023 [5] Group 3: Cost Pressures and Profitability - Cost pressures are intensifying, squeezing net profit margins across the industry, with Tailin Bio facing significant profit margin erosion due to raw material price increases and price wars [6] - Despite a 15.01% year-on-year revenue growth, Lihua Technology experienced a decline in net profit due to rising costs and increased expenses [6] - Companies like Nanwei Technology have successfully implemented quality improvement and efficiency enhancement measures, restoring growth in core business areas while controlling expenses [6] Group 4: Executive Compensation Trends - The average pre-tax salary of executives has decreased to approximately 860,000 yuan, down from 1.2 million yuan last year, reflecting cost-cutting measures amid profit pressures [9] - The compensation structure for executives in the instrument industry is evolving, emphasizing the importance of strategic transformation, industry upgrades, and cost management [9]